These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32006)

  • 1. Labetalol in hypertensive patients with angina pectoris: beneficial effect of combined alpha- and beta-adrenoreceptor blockade.
    Lubbe WF; White DA
    Clin Sci Mol Med Suppl; 1978 Dec; 4():283s-286s. PubMed ID: 32006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Labetalol therapy in patients with systemic hypertension and angina pectoris: effects of combined alpha and beta adrenoceptor blockade.
    Frishman WH; Strom JA; Kirschner M; Poland M; Klein N; Halprin S; LeJemtel TH; Kram M; Sonnenblick EH
    Am J Cardiol; 1981 Nov; 48(5):917-28. PubMed ID: 6118060
    [No Abstract]   [Full Text] [Related]  

  • 3. Beneficial effect of labetalol in hypertensive patients with angina pectoris.
    Lubbe WF; White DA
    S Afr Med J; 1983 Jan; 63(3):67-71. PubMed ID: 6849167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind trial comparing labetalol with atenolol in the treatment of systemic hypertension with angina pectoris.
    Jee LD; Opie LH
    Am J Cardiol; 1985 Sep; 56(8):551-4. PubMed ID: 3929584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternatives to beta-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol.
    Opie LH; White D; Lee J; Lubbe WF
    Br J Clin Pharmacol; 1982 Jun; 13(1 Suppl):115S-122S. PubMed ID: 7093094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open evaluation of labetalol in the treatment of angina pectoris occurring in hypertensive patients.
    Besterman EM; Spencer M
    Br J Clin Pharmacol; 1979; 8(Suppl 2):205S-209S. PubMed ID: 526402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of combined alpha and beta adrenoceptor blockade in patients with angina pectoris. A double blind study comparing labetalol with placebo.
    Quyyumi AA; Wright C; Mockus L; Shackell M; Sutton GC; Fox KM
    Br Heart J; 1985 Jan; 53(1):47-52. PubMed ID: 3881105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Labetalol, a new alpha- and beta-adrenoreceptor blocking agent, in hypertension.
    Hansson L; Hänel B
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):763-4. PubMed ID: 10952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Labetalol in the treatment of angina pectoris.
    Kanto JH
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):166-74. PubMed ID: 2881899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Labetalol compared with propranolol in patients with both angina pectoris and systemic hypertension: a double-blind study.
    Frishman WH; Shapiro W; Charlap S
    J Clin Pharmacol; 1989 Jun; 29(6):504-11. PubMed ID: 2666451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha- and beta-blockade in angina pectoris.
    Taylor SH
    Drugs; 1984; 28 Suppl 2():69-87. PubMed ID: 6151892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.
    Mehta J; Cohn JN
    Circulation; 1977 Feb; 55(2):370-5. PubMed ID: 12880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part II. Effects of oral labetalol in patients with both angina pectoris and hypertension: a preliminary experience.
    Halprin S; Frishman W; Kirschner M; Strom J
    Am Heart J; 1980 Mar; 99(3):388-96. PubMed ID: 7355700
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral labetalol in the management of stable angina pectoris in normotensive patients.
    Upward JW; Akhras F; Jackson G
    Br Heart J; 1985 Jan; 53(1):53-7. PubMed ID: 3917674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Labetalol: an alpha- and beta-blocker.
    Conner CS
    Drug Intell Clin Pharm; 1983; 17(7-8):543-4. PubMed ID: 6135593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
    Prichard BN
    Drugs; 1984; 28 Suppl 2():51-68. PubMed ID: 6151891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test responses.
    Prida XE; Hill JA; Feldman RL
    Am J Cardiol; 1987 May; 59(12):1084-8. PubMed ID: 2883869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina.
    Opie LH
    Cardiovasc Drugs Ther; 1988 Sep; 2(3):369-76. PubMed ID: 3154919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Labetalol, an alpha- and beta-adrenergic blocking drug in the treatment of hypertension.
    Rosei EA; Fraser R; Morton JJ; Brown JJ; Lever AF; Robertson JI; Trust PM
    Am Heart J; 1977 Jan; 93(1):124-5. PubMed ID: 12654
    [No Abstract]   [Full Text] [Related]  

  • 20. Haemodynamic effects of combined alpha- and beta-adrenoreceptor blockade after intravenous labetalol in hypertensive patients at rest and during exercise.
    Koch G
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):725-8. PubMed ID: 10950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.